StockNews.com Downgrades Collegium Pharmaceutical (NASDAQ:COLL) to Buy

Collegium Pharmaceutical (NASDAQ:COLL) was downgraded by equities research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Wednesday.

A number of other equities analysts have also recently commented on COLL. Piper Sandler reissued a “neutral” rating and set a $37.00 target price on shares of Collegium Pharmaceutical in a report on Friday, October 11th. HC Wainwright boosted their price target on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, September 5th. Needham & Company LLC reissued a “hold” rating on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. Finally, Truist Financial increased their price target on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, Collegium Pharmaceutical presently has an average rating of “Moderate Buy” and an average target price of $42.60.

Collegium Pharmaceutical Stock Down 0.7 %

Shares of COLL stock opened at $36.19 on Wednesday. The stock has a market cap of $1.18 billion, a P/E ratio of 15.08 and a beta of 0.94. Collegium Pharmaceutical has a twelve month low of $20.95 and a twelve month high of $42.29. The stock has a 50 day moving average of $37.66 and a 200 day moving average of $35.38. The company has a current ratio of 1.11, a quick ratio of 1.04 and a debt-to-equity ratio of 1.71.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.22. The business had revenue of $145.28 million for the quarter, compared to analyst estimates of $143.94 million. Collegium Pharmaceutical had a net margin of 17.32% and a return on equity of 107.62%. The company’s revenue for the quarter was up 7.2% on a year-over-year basis. During the same period in the prior year, the company posted $1.13 EPS. As a group, sell-side analysts expect that Collegium Pharmaceutical will post 5.79 EPS for the current year.

Insider Activity

In other Collegium Pharmaceutical news, EVP Thomas B. Smith sold 9,593 shares of the stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $36.62, for a total value of $351,295.66. Following the sale, the executive vice president now owns 53,816 shares of the company’s stock, valued at $1,970,741.92. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, EVP Thomas B. Smith sold 9,593 shares of the company’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $36.62, for a total transaction of $351,295.66. Following the completion of the transaction, the executive vice president now directly owns 53,816 shares of the company’s stock, valued at approximately $1,970,741.92. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of the firm’s stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $38.30, for a total transaction of $737,198.40. Following the sale, the executive vice president now directly owns 120,161 shares in the company, valued at approximately $4,602,166.30. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 3.98% of the company’s stock.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several large investors have recently modified their holdings of COLL. Janney Montgomery Scott LLC acquired a new position in Collegium Pharmaceutical in the 1st quarter valued at about $519,000. Texas Permanent School Fund Corp lifted its holdings in shares of Collegium Pharmaceutical by 1.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 28,541 shares of the specialty pharmaceutical company’s stock valued at $1,108,000 after buying an additional 369 shares during the period. Gallacher Capital Management LLC purchased a new stake in shares of Collegium Pharmaceutical in the first quarter valued at approximately $223,000. LSV Asset Management grew its stake in shares of Collegium Pharmaceutical by 188.7% during the 1st quarter. LSV Asset Management now owns 380,551 shares of the specialty pharmaceutical company’s stock worth $14,773,000 after purchasing an additional 248,751 shares during the period. Finally, Russell Investments Group Ltd. grew its position in Collegium Pharmaceutical by 3.2% during the first quarter. Russell Investments Group Ltd. now owns 33,084 shares of the specialty pharmaceutical company’s stock worth $1,284,000 after buying an additional 1,011 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.